Date: 2014-07-25
Type of information: Services contract
Compound: in-vitro cell line screening
Company: Horizon Discovery (UK) Otsuka Pharmaceutical Development and Commercialization (Japan)
Therapeutic area: Technology - Services
Type agreement: services
Action mechanism:
Disease:
Details: * On July 25, 2014, Horizon Discovery, a provider of research tools to support translational genomics and the development of personalized medicines, announced its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization, to perform in vitro cell line screening of certain OPDC development candidate(s). Horizon Discovery completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014. Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations. Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, the company offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.
Financial terms: Pursuant to the terms of the contract, Horizon CombinatoRx will be paid $835,000 for work to be substantially completed during 2014.
Latest news:
